Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. tumourprint

TUMOURPRINT SIGNED

High Throughput Bioprinting of Tumour Models for Drug Development and Oncology Research

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 TUMOURPRINT project word cloud

Explore the words cloud of the TUMOURPRINT project. It provides you a very rough idea of what is the project "TUMOURPRINT" about.

grown    implications    market    pay    rely    track    human    specially    optimal    commercialised    collaborations    bioprinting    world    tumourprint    willingness    2016    precise    formulated    commercialized    mimicking    robotics    cancer    reproducible    vascularity    establishment    designed    attrition    size    18    bioink    commercialise    automated    unsatisfactory    giants    models    analytical    capacity    ten    clinical    ing    principally    constructs    heterogeneity    none    live    company    drug    bioprinters    countries    combination    printed    proper    tissue    organisation    bioinks    fabricating    global    commercialising    trials    drive    secured    3d    2d    record    microenvironment    first    candidates    hydrogels    instructive    environment    fidel    cells    tumour    animal    predict    unparalleled    serial    proposition    oncology    universal    successfully    producing    generations    revolutionise    cellink    completely    rates    printing    ethically    constitutes    offers    cell    disruptive    outcomes    economic    survival    mono    failed    throughput    platform    pharmaceutical    destructive    scoring    cultures    proven    exasperatingly    fold    humans   

Project "TUMOURPRINT" data sheet

The following table provides information about the project.

Coordinator		 CELLINK AB 

Organization address
address: ARVID WALLGRENS BACKE 20
city: GOTEBORG
postcode: 413 46
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Sweden [SE]
 Project website https://cellink.com/global/
 Total cost 3˙500˙467 €
 EC max contribution 2˙450˙327 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2021-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CELLINK AB SE (GOTEBORG) coordinator 2˙450˙327.00

Map

 Project objective

CELLINK will develop and commercialise TumourPrint - a high throughput platform for bioprinting of live tumour models for pharmaceutical drug development and large-scale cancer research. Bioprinting constitutes the most advanced method for fabricating fidel tissue models, using live cells in combination with cell-instructive bioinks (specially formulated hydrogels that provide cells with an optimal environment for survival, growth and proper 3D development).

The high throughput platform - completely new to the market - is designed according to user needs. It will revolutionise drug development processes through serial production of fidel cancer models in an automated, precise and reproducible way. The platform offers unparalleled printing capacity and is integrated with robotics and none-destructive analytical methods capable of scoring drug responses in printed constructs.

Current oncology approaches principally rely on unsatisfactory 2D mono-cell cultures and animal models to predict outcomes in humans, resulting in exasperatingly high attrition rates of cancer drug candidates in clinical trials. The economic and ethically challenging implications of failed trials provide CELLINK with a unique value proposition to drive willingness-to-pay for their disruptive platform. TumourPrint will address today’s pharmaceutical challenges by producing tumour models capable of mimicking size, heterogeneity and vascularity of the human tumour microenvironment in a fidel way.

CELLINK has a proven track-record of successfully developing and commercialising products according to user needs; they developed the world’s first universal bioink, have commercialized three generations of bioprinters and optimised 18 cell-specific bioinks. Since the company’s establishment in 2016, CELLINK has commercialised its technology in over 40 countries, grown its organisation ten-fold and secured collaborations with several global pharmaceutical giants.

 Deliverables

List of deliverables.
Cancer cell lines selected Documents, reports 2019-11-28 17:30:38
10 hired employees Demonstrators, pilots, prototypes 2019-11-28 17:30:39

Take a look to the deliverables list in detail:  detailed list of TUMOURPRINT deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TUMOURPRINT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TUMOURPRINT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Read More  

Click and Spray (2020)

A SIMPLER, CHEAPER AND EASIER TO RECYCLE AEROSOL CONTAINER

Read More